Search results
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 4 days agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com
ETF DAILY NEWS· 8 hours agoStockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report issued on Saturday. The firm issued a sell rating on the stock. Ayala Pharmaceuticals ...
3 Underappreciated Stocks That Could 10x in 10 Years
InvestorPlace via Yahoo Finance· 7 days agoLike achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter...
Local Leukemia & Lymphoma Society holds annual fundraiser for blood cancer research
Local 12 Cincinnati· 3 days agoThe local chapter of the Leukemia and Lymphoma Society held its annual fundraiser to raise money for...
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
FOX 23 News Albany· 6 days agoMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses ...
Joyce Annette (Kohlmeier) Trosper
McCook Daily Gazette· 5 days agoJoyce Annette (Kohlmeier) Trosper Jan. 13, 1949 - May 12, 2024 CAMBRIDGE, Neb. - Joyce Annette (Kohlmeier) Trosper, age 75, passed away on May 12, 2024, at the Tri-Valley Hospital in Cambridge ...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 6 days agoThe company has secured a composition of matter patent for Annamycin, ensuring market exclusivity...
Earnings call: Bio-Path Holdings reports promising Q1 2024 results By Investing.com
Investing.com· 4 days agoBio-Path Holdings (NASDAQ: NASDAQ:BPTH), a biotechnology company focused on developing therapeutic...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 6 days agoThe company has secured a composition of matter patent for Annamycin, ensuring market exclusivity...
Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to Hold
ETF DAILY NEWS· 3 days agoStockNews.com upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning. Several other ...
